EVLO vs. SPRC, EVFM, SBFM, BLPH, HSTO, CMRA, SXTC, GRI, BDRX, and APVO
Should you be buying Evelo Biosciences stock or one of its competitors? The main competitors of Evelo Biosciences include SciSparc (SPRC), Evofem Biosciences (EVFM), Sunshine Biopharma (SBFM), Bellerophon Therapeutics (BLPH), Histogen (HSTO), Comera Life Sciences (CMRA), China SXT Pharmaceuticals (SXTC), GRI Bio (GRI), Biodexa Pharmaceuticals (BDRX), and Aptevo Therapeutics (APVO). These companies are all part of the "pharmaceutical preparations" industry.
SciSparc (NASDAQ:SPRC) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership, community ranking and risk.
SciSparc has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Evelo Biosciences has a beta of 1.94, indicating that its share price is 94% more volatile than the S&P 500.
In the previous week, SciSparc had 2 more articles in the media than Evelo Biosciences. MarketBeat recorded 2 mentions for SciSparc and 0 mentions for Evelo Biosciences. Evelo Biosciences' average media sentiment score of 1.44 beat SciSparc's score of 0.00 indicating that SciSparc is being referred to more favorably in the media.
Evelo Biosciences received 168 more outperform votes than SciSparc when rated by MarketBeat users. However, 66.67% of users gave SciSparc an outperform vote while only 60.50% of users gave Evelo Biosciences an outperform vote.
25.1% of SciSparc shares are owned by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are owned by institutional investors. 1.5% of SciSparc shares are owned by insiders. Comparatively, 1.0% of Evelo Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
SciSparc has higher revenue and earnings than Evelo Biosciences.
Summary
SciSparc beats Evelo Biosciences on 8 of the 10 factors compared between the two stocks.
Get Evelo Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for EVLO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EVLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Evelo Biosciences Competitors List
Related Companies and Tools
